1. |
Law CC, Fu YT, Chau KK, et al. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for chinese patients with stageⅢ colon cancer[J]. J Dis Colon Rectum 2007, 50(12): 2180-2187.
|
2. |
Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the multidisciplinary oncology group on gastrointestinal tumors[J]. Anticancer Drugs, 2008, 19(1): 91-96.
|
3. |
Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase Ⅲ study[J]. J Clin Oncol, 2001, 19(21): 4097-4106.
|
4. |
Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase Ⅲ study[J]. J Clin Oncol, 2001, 19(8): 2282-2292.
|
5. |
Glynne-Jones R, Dunst J, Sebag-Montefiore D, et al. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?[J]. Ann Oncol. 2006, 7(3): 361-371.
|
6. |
Patt YZ, Lee FC, Liebmann JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI Regimen) as first-line chemotherapy for metastatic colorectal cancer phaseⅡ trial results[J]. Am J Clin Oncol, 2007, 30(4): 350-357.
|
7. |
Drewinko B, Yang LY. Cellular basis for the inefficacy of 5-FU in human colon carcinoma[J]. Cancer Treat Rep, 1985, 69(12): 1391-1398.
|
8. |
Maxwell Summerhayes. Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer[J]. Oncol Pharm Prac, 2001, 7(4): 107-125.
|
9. |
Smalley SR, Kimler BF, Evans RG, et al. Heterogeneity of 5-fluorouracil radiosensitivity modulation in cultured mammalian cell lines[J]. Int J Radiat Oncol Biol Phys, 1992, 24(3): 519-525.
|
10. |
秦鑫添, 王希成, 李玉齐, 等. 卡培他滨治疗晚期结直肠癌发生手足综合征与疗效的观察[J]. 临床医学工程, 2011, 18(2): 221-223.
|
11. |
Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phaseⅢ trials[J]. Br J Cancer, 2004, 90(6): 1190-1197.
|
12. |
Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellularDNA[J]. Mol Pharmacol, 2000, 58(5): 920-927.
|
13. |
Mathé G, Kidani Y, Triana K, et al. A phaseⅠ trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP)[J]. Biomed Pharmacother, 1986, 40(10): 372-376.
|
14. |
Van Cutsem E, Twelves C, Cassidy J, et al. Xeloda Colorectal Cancer Study Group Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phaseⅢ study[J]. J Clin Oncol, 2001, 19(21): 4097-4106.
|
15. |
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
|
16. |
Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer[J]. Acta Oncol, 2003, 42(8): 832-836.
|
17. |
梁堃, 李云峰. 卡培他滨联合奥沙利铂治疗老年晚期大肠癌疗效观察[J]. 现代肿瘤医学, 2008, 16(8): 1365-1366.
|
18. |
Kakolyris S, Souglakos J, Polyzos A, et al. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy[J]. Oncology, 2008, 74(1-2): 31-36.
|
19. |
Santini D, Vincenzi B, La Cesa A, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil and irinotecan resistant advanced colorectal cancer patients[J]. Oncology, 2005, 69(1): 27-34.
|
20. |
Seymour MT. Group UNCCS: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing(MRC FOCUS): A 2135-patient randomized trial in advanced colorectal cancer(ACRC) [J]. J Clin Oncol, 2005, 23(4): 16.
|
21. |
Waddell T, Gollins S, Soe W, et al. PhaseⅡ study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study[J]. Cancer Chemother Pharmacol, 67(5): 1111-1117.
|
22. |
Krishnamurthi SS, Brell JM., Hoppel CL, et al. PhaseⅠ clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine[J]. Cancer Chemother Pharmacol, 2009, 63(3): 441-450.
|
23. |
Cathomas R, Köberle D, Ruhstaller T, et al. Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?[J]. Support Care Cancer, 2010, 18(10): 1263-1270.
|
24. |
Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camp-tothecin, a novel water-soluble derivative of camptothecin, against murine tumors[J]. Cancer Res, 1987, 47(22): 5944-5947.
|
25. |
Fuchs C, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study[J]. J Clin Oncol, 2008, 26(4): 689-690.
|
26. |
Park SH, Bang SM, Cho EK, et al. First-Line Chemotherapy with Irinotecan plus Capecitabine for Advanced Colorectal Cancer[J]. Oncology Oncology, 2004, 66(5): 353-357.
|
27. |
Fuchs CS, MooreMR, H arker G, et al. PhaseⅢ comparison of two irinotecan dos ing regimens in second-line therapy of metastatic colorectal cancer[J]. Clin Oncol, 2003, 21(5): 807-814.
|
28. |
Zhang A, Xing Q, Q in S, et al. Intra-ethnic differences in genetic variants of the UGT-glucuronosyl transferase 1A1 gene in Chinese populations[J]. Pharmacogenomics J, 2007, 7(5): 333-338.
|
29. |
耿梅, 马韬, 徐昊平, 等. 伊立替康联合卡培他滨二线治疗38例晚期结直肠癌的临床观察[J]. 现代肿瘤医学, 2009, 17(7): 1305-1307.
|
30. |
Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase Ⅲ trial in first-line metastatic colorectal cancer (MCRC)[J]. J Clin Oncol, 2007, 25(18): 4030.
|
31. |
Kakolyris S, Souglakos J, Polyzos A, et al. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase Ⅱ study[J]. Oncology, 2008, 74(1-2): 31-36.
|
32. |
Zarate R, Rodriguez J, Bandres E, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis[J]. Br J Cancer, 2010, 102(6): 987-994.
|
33. |
Chong G, Dickson JL, Cunningham D, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan[J]. Br J Cancer, 2005, 93(5): 510-514.
|
34. |
Popov I, Tarabar D, Jovanović D, et al. Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in adcanced colorectal cancer[J]. Arch Oncol, 2007, 15(1-2): 10-14.
|
35. |
Wong A, Nowacki MP, Abt M, et al. Capecitabine as adjuvant treatment for stageⅢ colon cancer[J]. N Engl J Med, 2005, 4(5): 315-323.
|
36. |
Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial[J]. Br J Cancer, 2006, 94(8): 1122-1129.
|
37. |
Leonard GD, Brenner B, Kemeny NE, et al. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma[J]. J Clin Oncol, 2005, 171(66): 121-246.
|
38. |
Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance[J]. J Clin Oncol, 2006, 24(4): 668-672.
|
39. |
徐志巧, 李宁, 帖晓静, 等. 奥沙利铂和希罗达或醛氢叶酸等治疗结直肠癌研究[J]. 医药论坛杂志, 2007, 28(8): 59-60.
|